No abstract

No abstract

The relevance of the diversity of endothelial cells (ECs) for the response to inflammatory stimuli is currently not well defined. Using oligonucleotide microarray technique, we systematically analyzed the tumor necrosis factor (TNF)-induced expression profile in human microvascular ECs (HMEC) and macrovascular human umbilical vein ECs (HUVEC), analyzing 13,000 human genes by microarray analysis. Using strict inclusion and exclusion criteria, microarray analysis revealed that about half of the TNF-induced genes were specific for HMEC-1 or HUVEC. The microarray data could widely be confirmed by quantitative reverse transcriptase-polymerase chain reaction and at the protein level. It is interesting that the majority of those genes regulated depending on the cell type encoded for chemokines, cytokines, and cell surface molecules. Our results argue for a more careful consideration of specific effects restricted to distinct subtypes of ECs. The establishment of EC type-specific expression patterns may thus provide the basis for a selective manipulation of specific endothelial subtypes in different inflammatory diseases.

Nickel compounds are prime inducers of contact allergy reactions in humans. To identify the signal transduction pathways mediating the cellular responses to nickel and to elucidate their hierarchy, we performed Affymetrix gene profiling using human primary endothelial cells, which strongly respond to nickel stimulation. Overall, we found 258 significantly modulated transcripts, comprising 140 up-regulated and 118 down-regulated genes. The bulk of those genes were identified as targets of two distinct signaling cascades, the IKK2/NF-B pathway and a proangiogenic pathway mediated by HIF-1␣, which accumulates upon exposure to nickel. Using dominant-interfering mutants and retroviral RNA interference technology, we demonstrate that both pathways act independently to regulate expression of nonoverlapping gene pools. NF-B activation mediates most of the proinflammatory responses to nickel. Nickel-dependent HIF-1␣ activation primarily modulates expression of genes involved in proliferation, survival, metabolism, and signaling, albeit the induction of some proinflammatory nickel-response genes, most prominently IL-6, which we identified as novel bona fide HIF-1␣ target in this study, is also critically dependent on this pathway. Furthermore, we provide evidence that transactivation of both transcription factors partially depends on p38 MAPK activation that contributes to the intensity of at least some target genes. Taken E ndothelial cells (ECs),3 located between blood and tissue compartments are important components of the innate immune system. Their activation by endogenous or environmental factors is a key event in the initiation of inflammatory responses. A strong activator of endothelium is the transition metal nickel that is widely distributed in a multitude of products. Contact with nickel is potentially hazardous for health: nickel compounds not only act as carcinogens in humans and animals (1) but also represent potent allergens (haptens). In industrialized countries, nickel is the most frequent cause for contact hypersensitivity reactions (2) with an estimated rate of 39% of young women being sensitized (3). Nickel is furthermore of great relevance in the context of biocompatibility of cardiovascular stents and orthopedic and dental biomedical alloys (4 -6). Nickel ions exert proinflammatory and irritant properties, which, in addition to their sensitizing capacity, provide a "second signal" in hypersensitivity reactions (7).Studying primary ECs, we earlier demonstrated that divalent nickel ions are capable of directly inducing endothelial adhesion molecules such as ICAM-1, VCAM-1, and E-selectin (8). Further analysis revealed that transcription of these genes is mediated via the IKK2/IB␣/NF-B signal transduction pathway, which is activated in response to soluble nickel compounds but not to other divalent cations (9, 10). NF-B activation is initiated by IKK2-mediated phosphorylation and subsequent proteasomal degradation of IB proteins, which allows nuclear translocation and binding of the transcription factor...

No abstract

Patients with psoriasis have an increased risk of cardiovascular disease that is partly attributable to chronic systemic inflammation. The aim of our prospective pilot study was to investigate the impact of fumaric acid esters (FAE), a first-line systemic antipsoriatic treatment in Germany, on cardiovascular risk parameters. Participants with moderate-to-severe psoriasis from the University Medical Center Mannheim and the University Hospital Würzburg were treated with FAE for 16 weeks according to standard dosage recommendations. Disease severity, life quality and depression scores as well as biomarkers of inflammation, lipid and glucose metabolism were assessed prior to initiation of FAE and after 16 weeks. Out of 39 participants recruited, 27 completed the study. 44% of all participants and 63% of those completing the 16-week treatment achieved PASI 50 response and 27 or 37% PASI 75 response. Clinical improvement was paralleled by significant improvement in quality of life, high treatment satisfaction and significant reduction of depressive symptoms. Adverse events, most frequently mild gastrointestinal complaints, flush and lymphocytopenia occurred in 89%. FAE did not modify glucose metabolism or inflammatory parameters substantially. However, a highly significant increase in serum levels of the atheroprotective cytokine adiponectin was noted after 16 weeks (median 4.7 vs. 8.9 µg/ml; p = 0.0002). Our study demonstrates a significant beneficial impact of FAE on adiponectin, indicating a potential cardioprotective effect. It will be interesting to verify this finding in larger cohorts and to assess the long-term influence of FAE on cardiovascular risk and disease.

Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Here, we perform whole-exomesequencing and genome-wide genotyping in 145 patients (median age-at-diagnosis of 3.5 years), in whom no Mendelian disorders were clinically suspected. In five patients we detect a primary immunodeficiency or enteropathy, with clinical consequences (XIAP, CYBA, SH2D1A, PCSK1). We also present a case study of a VEO-IBD patient with a mosaic de novo, pathogenic allele in CYBB. The mutation is present in~70% of phagocytes and sufficient to result in defective bacterial handling but not life-threatening infections. Finally, we show that VEO-IBD patients have, on average, higher IBD polygenic risk scores than population controls (99 patients and 18,780 controls; P < 4 × 10 −10 ), and replicate this finding in an independent cohort of VEO-IBD cases and controls (117 patients and 2,603 controls; P < 5 × 10 −10 ). This discovery indicates that a polygenic component operates in VEO-IBD pathogenesis.